News Direct https://www.newsdirect.com Thu, 19 Nov 2026 18:02:47 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.5 https://www.newsdirect.com/wp-content/uploads/2024/08/cropped-NewsDirect_MarkONNAVY_RGB-32x32.png News Direct https://www.newsdirect.com 32 32 Carlos Ponce to Meet Fans at Christmas Wonderland Miami’s Pure Flix Familia Lodge on Black Friday, Nov. 27 https://www.newsdirect.com/newsroom/carlos-ponce-to-meet-fans-at-christmas-wonderland-miamis-pure-flix-familia-lodge-on-black-friday-nov-27/ Thu, 19 Nov 2026 18:02:47 +0000 https://www.newsdirect.com/?p=55133 Miami, FL, November 19th, 2026, NewsDirect

— Pure Flix Familia, Great American Media’s new Latino-focused streaming service, hosts a festive holiday Lodge at Christmas Wonderland, open through Jan. 3, 2027 —

— Fans can take photos with Ponce from 6 to 10 p.m. at Tropical Park, and new subscribers can save 50% on their first year —

Pure Flix Familia, Great American Media recently launched streaming service offering wholesome entertainment for Latino families, is hosting a meet and greet, free with Christmas Wonderland admission, with actor-producer Carlos Ponce at the Pure Flix Familia Lodge at Christmas Wonderland in Miami’s Tropical Park on Black Friday, Nov. 27, from 6 to 10 p.m.

Open all season, the Lodge gives families a fireplace backdrop for holiday photos and a preview of Pure Flix Familia’s Christmas lineup, including Alquilé un Novio para Navidad, Un Regalo… Navideño and Three Generations, One Christmas. Each title reflects what Pure Flix Familia stands for: uplifting stories celebrating love, faith and family that parents can feel good about sharing with their kids.

Ponce is a co-founder of Minivela, the Latino media, entertainment and production company and a Great American Media partner. He is helping shape Pure Flix Familia’s creative identity, build relationships with actors, writers and filmmakers, and support audience-engagement initiatives. He is also expected to appear in future Pure Flix Familia projects.

Launched in Spanish and expanding into English-language and bilingual storytelling, Pure Flix Familia is made for every generation at the table, from abuelos to the grandkids.

A Holiday Gift for Founding Members 

This Christmas, families can be among the first to call Pure Flix Familia home. Lodge visitors can choose from two holiday offers: a full year for $24.99 (regularly $49.99) with code WONDERLAND50, or 50% off the first month (regularly $4.99) with code FAMILIA50. Offers valid for new subscribers through Dec. 31, 2026. To join, scan the QR codes at the Lodge or visit pureflixfamilia.com. Founding members who sign up at the Lodge can take home Spanish-language holiday merch, including T-shirts, sweatshirts, caps and beanies, while supplies last.

Event Details

What: Meet & Greet with Carlos Ponce at the Pure Flix Familia Lodge

When: Friday, Nov. 27, 2026 (Black Friday), 6 to 10 p.m.; park open 4 p.m. to midnight Where: Tropical Park, 7900 SW 40th St., Miami, FL 33155

Pure Flix Familia Lodge: Town Square, near the main entrance

Christmas Wonderland Dates: Nov. 12, 2026 – Jan. 3, 2027

Tickets and Information: miamiwonderland.com

About Pure Flix Familia

Pure Flix Familia is Great American Media’s Latino-focused streaming destination for culturally relevant entertainment centered on family and faith. Created around a Total Latino Market strategy, the platform is designed to serve Spanish-dominant, bilingual and English-dominant audiences through movies, series, original microdramas and curated programming that families can confidently enjoy together.

About Great American Media

Great American Media is the leader in faith and family entertainment, and one of the fastest-growing entertainment networks on television. Great American Media is home to a portfolio of entertainment brands that celebrate faith, family, and country, including Great American Family, the flagship linear network featuring original Christmas movies, rom-coms, and beloved series; Great American Pure Flix, the leading faith and family streaming service; Great American Faith & Living, the unscripted companion network; and GFam+, an app that lets viewers watch anytime, anywhere. Great American Media, established in June 2021 by Bill Abbott and a group of US-based family offices, is available via cable, streaming on Pure Flix and YouTube TV, and on the GFam+ app.

About Minivela

Minivela is a bilingual microdrama company creating, producing, distributing, and monetizing culturally relevant, brand-friendly entertainment for U.S. Hispanic and Latin American audiences. Its original productions, creator collaborations, branded entertainment, and media partnerships connect storytelling, audiences, and commerce. Projects and partnerships include Rico’s Tacos and Pure Flix Familia.

Contact

Victoria Quevedo Or Debbie Davis
[email protected]
512-537-1414

]]>
Guidepoint and Rogo Partner to Bring Guidepoint Library Insights into AI Powered Financial Research https://www.newsdirect.com/newsroom/guidepoint-and-rogo-partner-to-bring-guidepoint-library-insights-into-ai-powered-financial-research/ Thu, 19 Nov 2026 17:47:56 +0000 https://www.newsdirect.com/?p=55130 New York, NY, November 19th, 2026, NewsDirect

Bankers and investors using Rogo can access Guidepoint Library insights, including 150,000+ compliance-reviewed expert transcripts, with answers cited to the original conversation

Guidepoint, a global pioneer in access to expert insight, today announced a partnership with Rogo, the leading AI operating system for financial services and a trusted partner to the world’s most prestigious financial institutions. Through the Guidepoint MCP connector, Guidepoint clients who use Rogo can access Guidepoint Library insights from vetted Advisors in the same platform where they already build comps, models, memos, and pitchbooks.

AI is changing how financial professionals conduct research, but an AI-generated answer is only as trustworthy as the information behind it. The partnership pairs Guidepoint’s curated, compliance-reviewed Library content with Rogo’s AI platform, and answers that draw on Guidepoint content are cited directly to the source.

“From our very first conversation, it was clear that Rogo and Guidepoint share a commitment to giving clients reliable insight grounded in the firsthand experience of vetted practitioners,” said Ameesh Shah, Chief Commercial Officer, Guidepoint Insights at Guidepoint. “By combining our strengths, we are streamlining critical workflows, reducing everyday friction, and helping clients get to the answers they need faster. This partnership creates a more unified experience that helps users focus on what matters most.”

The Guidepoint Library includes more than 150,000 compliance-reviewed transcripts of moderated conversations with vetted Advisors who bring relevant industry experience, and more than 5,000 new expert interviews are added every month. Guidepoint curates this content around topics relevant to clients’ research needs, helping deal teams and investors incorporate additional perspectives as they screen opportunities, evaluate theses, and prepare client deliverables.

“Some of the most valuable insights in finance come from people who have actually operated the businesses and navigated the markets our customers are analyzing,” said Strib Walker, Head of Product at Rogo. “Our partnership with Guidepoint brings that expertise directly into Rogo, so teams can incorporate firsthand industry perspectives into everything from diligence to investment decisions, without interrupting their workflows.”

Partnership Overview

  • Expert perspectives: perspectives from vetted Advisors with direct operating, customer, and competitor experience.
  • Traceable answers: Guidepoint-informed answers in Rogo cite the original transcript, which users can open to validate the answer.
  • Compliance review: every transcript is compliance-reviewed, and Guidepoint implements custom compliance controls tailored to each firm’s requirements.
  • Built into existing workflows: insights appear where bankers and investors already work, with no need to switch tools.

The partnership is part of Guidepoint’s broader effort to make its expert research available across the AI platforms and workflows its clients rely on.

Availability

The Guidepoint MCP connector for Rogo is available now to Guidepoint clients using Rogo. To get connected, clients can contact their Guidepoint account team, contact us here, or email [email protected].

About Guidepoint

Guidepoint provides real-time access to expert insights, combining human expertise with AI-powered research tools to deliver knowledge at scale. Backed by a global network of more than 2M+ subject-matter experts, Guidepoint equips institutional investors, consulting firms, and corporations with the context they need across companies, markets, and trends. Through live, asynchronous, and agentic workflows, Guidepoint embeds expert knowledge directly into decision-making, turning answers into action when timing matters most. For more information, visit www.guidepoint.com.

About Rogo

Rogo is the leading AI operating system for financial services and a trusted partner to the world’s most prestigious financial institutions across investment banking, private equity, asset management, and equity research. Rogo helps financial professionals expand what their firms can accomplish by amplifying expertise, accelerating workflows, and unlocking institutional intelligence. Rogo’s platform unifies internal knowledge, proprietary data, and trusted third-party research into a single operating system designed to think the way financial professionals do, enabling faster decisions, deeper insights, and more effective execution.

Contact

Meir Kahtan
Meir Kahtan Public Relations
[email protected]

]]>
Beeline Holdings (NASDAQ: BLNE) Enters Definitive Agreement to Acquire Blockchain-Based Real Estate Equity Platform TYTL https://www.newsdirect.com/newsroom/beeline-holdings-nasdaq-blne-enters-definitive-agreement-to-acquire-blockchain-based-real-estate-equity-platform-tytl/ Thu, 19 Nov 2026 16:44:19 +0000 https://www.newsdirect.com/?p=55128 Austin, Texas, United States, November 19th, 2026, NewsDirect

Beeline Holdings (NASDAQ: BLNE) announced it has entered into a definitive merger agreement to acquire TYTL Corp., a blockchain-enabled residential real estate equity platform, in an all-stock transaction. The proposed acquisition would expand Beeline beyond digital mortgage origination into home equity investments, tokenized real estate securities and blockchain-enabled financial infrastructure. Existing Beeline shareholders are expected to initially retain approximately 60% of the combined company, with TYTL shareholders owning approximately 40%, subject to adjustments and the cancellation of certain shares otherwise issuable to Beeline CEO Nick Liuzza, who is also CEO and a principal shareholder of TYTL. A special committee of independent directors negotiated the transaction and obtained a third-party fairness opinion.

TYTL’s platform enables homeowners to access equity without traditional credit checks, monthly payments or conventional appraisals, while providing institutional investors access to tokenized residential real estate securities. Its business model targets transaction revenue equal to 8.5% of transaction value, along with retained digital securities representing approximately 5% of transaction value, which constitute potential asset value rather than recognized revenue. Beeline plans to leverage its artificial intelligence (“AI”) technology, mortgage operations and title infrastructure to support the platform’s expansion, with an initial addressable market estimated at $1 trillion. The company also expects to introduce a home equity investment-related digital token in January, subject to regulatory requirements. Closing remains contingent on several conditions, including approval by a majority of disinterested Beeline shareholders and TYTL securing at least $15 million in committed institutional capital.

To view the full press release, visit https://ibn.fm/t4mEe

About Beeline Holdings, Inc.

Beeline Holdings, Inc. is a technology-driven mortgage and home-finance company focused on simplifying and accelerating the path to homeownership, property investment and home-equity access. Through its digital platform, Beeline offers mortgage products designed for traditional borrowers, self-employed borrowers and real estate investors and is expanding its platform into home equity investment products.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

]]>
SS Innovations International (NASDAQ: SSII) Announces First Dual-Console, Five-Arm Robotic Beating-Heart Bypass Surgery https://www.newsdirect.com/newsroom/ss-innovations-international-nasdaq-ssii-announces-first-dual-console-five-arm-robotic-beating-heart-bypass-surgery/ Thu, 19 Nov 2026 16:43:53 +0000 https://www.newsdirect.com/?p=55126 Austin, Texas, United States, November 19th, 2026, NewsDirect

SS Innovations International (NASDAQ: SSII) announced the successful completion of what it describes as the world’s first dual-console, beating-heart totally endoscopic coronary artery bypass (“TECAB”) surgery utilizing all five arms of its SSi Mantra surgical robotic system. The procedure was performed at Medanta – The Medicity Hospital in Gurugram, India, by Dr. Nitin Kumar Rajput of Medanta Hospital and Dr. Lalit Malik of Manipal Hospital, Jaipur, under the guidance of SS Innovations Chairman and CEO Dr. Sudhir Srivastava. The surgeons operated simultaneously using separate control consoles, with all five robotic arms working in synchronization while a stabilization system steadied the surgical area.

The minimally invasive procedure enabled surgeons to perform coronary artery bypass surgery through small incisions without opening the chest or using a heart-lung machine, allowing the patient’s heart to continue beating throughout the operation. According to the company, the successful integration of dual-console control and five robotic arms represents an advancement in robotic cardiac surgery. Medanta Hospital Chairman and Managing Director Dr. Naresh Trehan reported that the patient was doing extremely well following the procedure, while SS Innovations highlighted the achievement as part of its mission to make advanced robotic surgery more affordable and accessible worldwide.

To view the full press release, visit https://ibn.fm/aY2Mk

About SS Innovations

SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.  Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.  Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

]]>
ZenaTech (NASDAQ: ZENA) Surpasses C$20 Million in Contracted Revenue Backlog Across Global Operations https://www.newsdirect.com/newsroom/zenatech-nasdaq-zena-surpasses-c20-million-in-contracted-revenue-backlog-across-global-operations/ Thu, 19 Nov 2026 16:43:34 +0000 https://www.newsdirect.com/?p=55124 Austin, Texas, United States, November 19th, 2026, NewsDirect

ZenaTech (NASDAQ: ZENA) (FSE: 49Q) (BMV: ZENA) announced that its consolidated contracted revenue backlog has surpassed C$20 million, or approximately US$14 million, reflecting signed customer commitments expected to generate revenue in future reporting periods. The backlog spans the company’s Drone as a Service (“DaaS”) and enterprise software-as-a-service (“SaaS”) businesses, providing greater visibility into future revenue as ZenaTech expands its global operations and integrates acquired businesses. Contracted work is expected to convert into recognized revenue over periods ranging from several weeks to several months as services are delivered and performance obligations are satisfied.

The company is strengthening sales, marketing and business development initiatives across its acquired DaaS businesses to pursue larger, multi-year contracts, expand government and commercial opportunities and cross-sell complementary services. ZenaTech is also integrating artificial intelligence (“AI”)-powered drone technology into its surveying, mapping, inspection and monitoring services to improve operating efficiency and scalability. Management anticipates potential additional revenue from ongoing negotiations, existing customer relationships and contract modifications. The company noted that contracted backlog does not represent revenue recognized under International Financial Reporting Standards (“IFRS”) or cash received and does not guarantee future revenue.

To view the full press release, visit https://ibn.fm/xkV7L

About ZenaTech

ZenaTech, Inc. is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

To learn more about ZENA, visit https://www.zenatech.com/

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to ZENA are available in the company’s newsroom at https://ibn.fm/ZENA

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

]]>
AZIO AI Holdings (NASDAQ: AZIO) Signs Agreement to Support $144.6M in U.S. Army Microgrid Contracts https://www.newsdirect.com/newsroom/azio-ai-holdings-nasdaq-azio-signs-agreement-to-support-144-6m-in-u-s-army-microgrid-contracts/ Thu, 19 Nov 2026 16:43:23 +0000 https://www.newsdirect.com/?p=55122 Austin, Texas, United States, November 19th, 2026, NewsDirect

AZIO AI Holdings (NASDAQ: AZIO) announced it has signed a general contracting agreement with Energy Resilience Partners LLC (“ERP”) to support two awarded U.S. Army microgrid contracts with a combined value of approximately $144.6 million, including options for increased capacity. ERP serves as prime contractor on both projects, with AZIO acting as general contractor for the approximately $45 million Fort Buchanan project in Puerto Rico and providing project-management support for the approximately $99.6 million, 15-megawatt project at the Lake City Army Ammunition Plant in Missouri. Each project is expected to take approximately three years once work begins, contingent upon delivery and acceptance of ERP’s performance and payment bonds.

The projects involve on-site power generation, battery storage and grid-independent operations, capabilities AZIO is also developing for its artificial intelligence (“AI”) infrastructure campuses through Project Atlas in Texas. The Fort Buchanan microgrid is designed to sustain operations independently of the commercial grid for up to 14 days. AZIO expects to recognize contract-based services revenue as work progresses, although the $144.6 million represents the value of ERP’s prime contracts rather than anticipated AZIO revenue. The company has not provided revenue or profit projections, and its compensation depends on ERP’s performance and payment under the Army contracts.

To view the full press release, visit https://ibn.fm/alOu3

About AZIO AI Holdings Inc.

AZIO AI Holdings is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions and digital asset mining operations.

The company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.

Through this diversified AI infrastructure strategy, the company is positioned to capitalize on the rapidly expanding global demand for AI infrastructure, compute capacity, digital power and next-generation AI technologies.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to AZIO are available in the company’s newsroom at https://ibn.fm/AZIO

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

]]>
Safe Pro Group (NASDAQ: SPAI) Reports Record Q3 2026 Revenue and Record AI Gross Margin https://www.newsdirect.com/newsroom/safe-pro-group-nasdaq-spai-reports-record-q3-2026-revenue-and-record-ai-gross-margin/ Thu, 19 Nov 2026 16:42:59 +0000 https://www.newsdirect.com/?p=55120 Austin, Texas, United States, November 19th, 2026, NewsDirect

  • Safe Pro Group reported record Q3 2026 revenue of $2,676,680, which is a 2,539% increase year-over-year and up over 100% sequentially compared to Q2 2026.
  • The company also reported a record 79% AI gross margin, with a major decrease in operating expenses, and a strong balance sheet.
  • Revenue increase was primarily driven by U.S. Army and other U.S. government-contracted sales.

Safe Pro Group Inc (NASDAQ: SPAI), a developer of AI-powered security and defense solutions, recently reported financial results for Q3 2026, which ended on September 30, 2026 (https://nnw.fm/DDih8).

Safe Pro recorded a record Q3 revenue of $2,676,680, which is an increase of 2,539% year-over-year, up around 101% sequentially compared to Q2 2026, and exceeded the preliminary estimate of more than $2.5 million. This revenue was primarily driven by U.S. Army and other U.S. government-contracted sales of Safe Pro’s AI-powered threat detection, edge compute, and…

Read More>>

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to SPAI are available in the company’s newsroom at https://ibn.fm/SPAI

Corporate Communications

IBN
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

Contact

IBN
www.InvestorBrandNetwork.com
[email protected]

]]>
Vesalius Longevity Labs Appoints Longevity Entrepreneur Dr. Peter Diamandis to Its Board of Directors https://www.newsdirect.com/newsroom/vesalius-longevity-labs-appoints-longevity-entrepreneur-dr-peter-diamandis-to-its-board-of-directors/ Thu, 19 Nov 2026 14:33:19 +0000 https://www.newsdirect.com/?p=55118 Vancouver, British Columbia, November 19th, 2026, NewsDirect

XPRIZE founder and globally recognized key opinion leader and entrepreneur joins a Board led by Chairman Harvey Spevak, alongside David Adelman, Kevin Mayer, Lee Applbaum, Dr. Kevin Serre, Robert McCue & James McRoberts

Vancouver, British Columbia–(November 19, 2026) – Vesalius Longevity Labs Inc. (CSE:VLAB) (“Vesalius” or the “Company“), a leading global peptide and longevity company, is pleased to announce the appointment of Dr. Peter Diamandis to its Board of Directors (the “Board“), effective November 19, 2026.

Dr. Diamandis is a highly recognized entrepreneur and thought leader in longevity, exponential technology and health innovation. He is the Founder and Executive Chairman of the XPRIZE Foundation; the Executive Founder of Singularity University; Co-founder and Chairman of Fountain Life, an integrated longevity and preventative health platform; and Co-founder of BOLD Capital Partners, a venture fund investing in exponential technologies. Over his career, Dr. Diamandis has founded more than 25 companies across health-tech, space, venture capital and education.

Dr. Diamandis holds degrees in molecular genetics and aerospace engineering from the Massachusetts Institute of Technology and an M.D. from Harvard Medical School. He is a New York Times bestselling author whose books include Abundance: The Future Is Better Than You Think, BOLD: How to Go Big, Create Wealth & Impact the World, The Future Is Faster Than You Think and the #1 bestseller LIFE FORCE, co-authored with Tony Robbins. Fortune has named him one of the “World’s 50 Greatest Leaders.”

As a Director, Dr. Diamandis will support Vesalius’s strategy across its peptide and longevity platform, scientific and clinical positioning, and strategic partnerships as the Company scales its provider network and brand globally.

“We are entering an era in which healthy human lifespan can be meaningfully extended, and peptides are one of the most promising and accessible resources we have to get there,” said Dr. Diamandis. “What excites me about Vesalius is its focus on putting rigorously sourced, U.S.-manufactured products and real clinical education into the hands of the physicians who are delivering longevity medicine today. I’m proud to join Harvey and this exceptional Board to help Vesalius scale that mission globally and make longevity care more trusted and more widely available.”

With the appointment of Dr. Diamandis, the Board now includes Harvey Spevak (Chairman), David Adelman, Kevin Mayer, Lee Applbaum, Kevin Serre, Robert McCue, and James McRoberts.

The Company also announces that Joel Leonoff has stepped down from the Board, effective November 19, 2026.

“Peter has spent his career in longevity and wellness and was instrumental in bringing longevity from the edges of science into the mainstream conversation,” said Harvey Spevak, Chairman of Vesalius. “He understands what it takes to turn breakthrough science into platforms that people trust. His vision, network and credibility will be invaluable as we build Vesalius into a category-defining global longevity brand. On behalf of the entire Board, I’m happy to welcome him to our Board. We would also like to thank Joel for his contributions to the Company and wish him well in his future endeavors.”

RSU Grants

The Company also announces that it has granted a total of 6,300,000 restricted share units (“RSUs“) to certain directors, officers, and consultants of the Company pursuant to the Company’s 10% rolling RSU Plan (the “Plan“).

Each RSU expires three (3) years from the grant date. Of the RSUs granted, 1,750,000 vest immediately on the grant date, 1,137,500 vest six (6) months following the grant date, 1,537,500 vest twelve (12) months following the grant date, 937,500 vest eighteen (18) months following the grant date, and 937,500 vest twenty-four (24) months following the grant date.

All RSUs are subject to the terms of the Plan, applicable securities law hold periods and the policies of the Canadian Securities Exchange.

About Vesalius

Vesalius Longevity Labs (CSE: VLAB) is a longevity and regenerative health platform focused on peptides, biologics and preventative healthcare. Vesalius’s proprietary ecosystem is designed to connect healthcare providers with trusted, compliant pharmacies and support the people they serve with access to quality therapies, education, and partnerships.

Through its announced collaboration with Celularity, the Company is developing a U.S. final-stage manufacturing and supply platform for its Peptual®-branded peptide APIs (active pharmaceutical ingredients) for domestic and international compounding supply chains in accordance with local laws and regulations. Vesalius’s vision is to deliver on the promise of longevity by enabling the future of personalized health and wellness.

Investors interested in learning more about Vesalius Longevity Labs are encouraged to contact the Company at:

https://www.vesaliuslabs.com/

For further information, please refer to the Company’s disclosure record on SEDAR+ at www.sedarplus.ca.

Investor contact:

Julia Becker

Vice President, Capital Markets

+1(604) 785-0850

[email protected]

Media contact: Jack Taylor Worldwide, [email protected]

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.

FORWARD-LOOKING INFORMATION

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation, including, without limitation, statements relating to: the Company’s global expansion plans and growth objectives; the advancement of Vesalius’s healthcare provider platform in the longevity space; the anticipated benefits of Dr. Diamandis’ appointment to the Board and his expected contributions to the Company’s growth and brand-building strategy; the Company’s intention to leverage Dr. Diamandis’ expertise in scaling premium wellness experiences; the scaling of the Company’s provider-led platform globally; the anticipated benefits of the exclusive manufacturing partnership with Celularity, Inc., including the development of a dedicated U.S. final stage API manufacturing and supply platform for the Company’s Peptual®-branded APIs; the advancement and commercialization of the Company’s Peptual®-branded peptide APIs; the Company’s ambition to build a category-defining brand that earns the trust of providers and patients; and the Company’s ability to shape the future of peptides and longevity.

Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. Forward-looking information involves known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks and uncertainties include, but are not limited to: the ability of the Company to successfully execute its global expansion strategy; the ability to retain and attract key personnel, including the anticipated contributions of Mr. Spevak; the ability of the Company to grow its healthcare provider network domestically and internationally; risks associated with the manufacturing partnership with Celularity, Inc., including regulatory approvals and manufacturing timelines; the ability of the Company to successfully develop and commercialize its Peptual®-branded APIs to cGMP standards; risks inherent in the biotechnology, pharmaceutical and wellness industries, including regulatory and competitive risks; the actual size and growth rate of the peptide therapeutics market differing materially from third-party projections; the Company’s ability to raise sufficient capital to fund its operations and growth plans; general economic and market conditions; and other risks described from time to time in the Company’s filings made available on SEDAR+ at www.sedarplus.ca.

Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information contained in this press release is expressly qualified in its entirety by this cautionary statement. The forward-looking information contained herein is made as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Featured Image @ Vesalius Longevity Labs Inc

Contact

Vice President, Capital Markets
Julia Becker
Vesalius Longevity Labs Inc.
[email protected]

]]>
AI Is Changing How Medicines Are Discovered. These 4 Stocks Are Positioned to Benefit (ANT, MEDS, RXRX, SDGR) https://www.newsdirect.com/newsroom/ai-is-changing-how-medicines-are-discovered-these-4-stocks-are-positioned-to-benefit-ant-meds-rxrx-sdgr/ Thu, 19 Nov 2026 13:41:48 +0000 https://www.newsdirect.com/?p=55115 Naples, FL, November 20th, 2026, NewsDirect

AI is increasingly becoming part of the drug discovery process, with researchers exploring how machine learning can identify therapeutic targets, design molecules, and accelerate the development of new treatments. The technology could help address some of the pharmaceutical industry’s longstanding challenges, including lengthy development timelines, high research costs, and the difficulty of identifying promising drug candidates. Recent developments are highlighting the growing commercial potential of AI-driven drug discovery, as companies push beyond theoretical applications and begin demonstrating how these tools can contribute to actual pharmaceutical research.

Anthropic recently outlined how its AI models are being used across drug development, detailing partnerships with six organizations working to develop new medicines. The applications range from generating roughly 35,000 antibody designs for a food allergy treatment to improving cancer-targeting molecules and reducing manufacturing documentation review time by 89% at Enveda. Bristol Myers Squibb is also using Claude to assess early-stage clinical trial plans.

The announcement highlights AI’s expanding role across drug discovery and development, from identifying targets and designing molecules to supporting clinical research. Several publicly traded companies are approaching this emerging field from different angles. Here are four stocks to take a closer look at.

DataMEDS AI, Inc. (NASDAQ:MEDS) is a Tampa, Florida-based healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform. The company recently announced that its wholly owned subsidiary Helomics, a CLIA-certified cancer diagnostics laboratory that DataMEDS acquired in September, entered a cancer target discovery and drug candidate optimization partnership with DiaGen.ai, an AI-driven drug discovery company based in Vancouver, Canada. Under the partnership, DiaGen gains access to the Helomics biobank, which holds more than 70,000 primary tumor biopsies, including more than 50,000 gynecologic cancer samples collected over nearly three decades.

The companies will first focus on validating 15 cytotoxic peptides that showed in vitro proof of concept in breast cancer cell lines, including triple-negative breast cancer. DiaGen will use its BLACKCOMB AI small-molecule design platform to build a library of drug candidates, Helomics will run the preclinical validation work on cell lines and primary tumors, and the two companies will jointly own the intellectual property that results. As part of the agreement, DataMEDS will issue 630,000 common shares to DiaGen, equal to 9.9% of its shares outstanding at the time of the agreement, and DiaGen will issue 9.9% of its fully diluted common shares to DataMEDS. The total value of the transaction is expected to be $1.5 million in cash and in-kind contributions through completion of project milestones.

DataMEDS has been active on other fronts as well. Its pharmacy subsidiary, Corexa Pharmacy, recently announced its first commercial sale of compounded peptides under the FDA’s enforcement discretion policy, and the company reported third-quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the second quarter, driven primarily by growth in Corexa Pharmacy drug dispensing. In November, DataMEDS also signed a non-binding memorandum of understanding with a Florida-based HMO to deploy its Health Lives Here mobile app to more than 25,000 members, with definitive agreements expected in the fourth quarter of 2026.

Anthropic (NASDAQ:ANT) is a San Francisco-based AI company founded in 2021 by siblings Dario Amodei, its CEO, and Daniela Amodei, its president, and it is structured as a public benefit corporation. Anthropic launched its Claude family of AI models commercially in early 2023, and businesses and individuals use Claude for tasks across industries, including coding, medicine, law, and science. The company sells Claude to enterprise customers and to individual subscribers, and its registration statement reported more than 11,900 customers generating $100,000 or more in trailing 12-month revenue as of September 30, 2026.

In January, Anthropic introduced Claude for Healthcare, a set of tools for health systems, insurers, and patients that runs on HIPAA-ready infrastructure, connects Claude to industry databases and medical coding systems, and lets individual users connect their own health records. Anthropic has since extended Claude further into life sciences, rolling out Claude Science, an AI workbench for researchers, and beginning drug discovery programs of its own, including through its acquisition of Mithril Medicine, a company developing treatments for two rare forms of muscular dystrophy.

Anthropic recently launched the roadshow for an initial public offering of Class A common stock and applied to list the shares on the Nasdaq Global Select Market under the symbol ANT.

Schrödinger, Inc. (NASDAQ:SDGR) is a computational drug discovery company that sells software built on a physics-based platform for molecular discovery and also runs its own drug discovery programs and collaborations. The company recently announced third-quarter 2026 results, reporting annual contract value of $44.7 million, up 17% from a year earlier, and trailing four-quarter annual contract value of $214 million, along with drug discovery revenue of $24 million. Schrödinger also increased its full-year 2026 guidance for annual contract value and drug discovery revenue.

In September, Schrödinger contributed two early-stage small-molecule programs, SDGR-4594 and SDGR-8139, to Tectora Therapeutics in connection with Tectora’s $55 million Series A financing, in exchange for an equity stake and eligibility for future milestones. Earlier this year, the company launched an early access version of Bunsen, an agentic AI co-scientist designed to plan and run molecular discovery workflows on its platform.

Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company that uses AI to discover and develop medicines, with a pipeline focused on oncology and rare diseases. The company recently announced its third-quarter 2026 results, reporting revenue of $18.55 million compared with $5.18 million a year earlier, driven mainly by a $10 million milestone payment from its collaboration with Sanofi, and a net loss of $119.0 million compared with $162.3 million in the same quarter last year. Recursion also said it extended its cash runway into 2029.

The company also presented new Phase 2 data for REC-4881 in familial adenomatous polyposis, a hereditary condition associated with gastrointestinal cancer risk. After 12 weeks of treatment, 87% of evaluable patients had reductions in total polyp burden, with a median reduction of 47%, and about one-third reached reductions of at least 65%. Recursion expects to begin a registrational study in the second half of 2027, pending discussions with the FDA. Separately, Sanofi has optioned a development candidate from the collaboration, and Genentech exercised its first Validated Target Option under the neuroscience collaboration.

Disclaimers: RazorPitch Inc. “RazorPitch” is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated $2500 by DataMEDS AI, Inc. to assist in the production and distribution of content related to CHGA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

About RazorPitch

RazorPitch is an investor relations and investor marketing firm specializing in Non-Traditional Investor Relations for public companies. RazorPitch complements traditional IR with digital-first investor visibility, retail investor engagement, and ongoing investor communications.

razorpitch.com

Contact

Editor
Mark McKelvie
RazorPitch
[email protected]
5853017700

]]>
Bluesight Tracks 340B Dollars from Invoice to Rebate as 2027 Brings New Financial and Operational Challenges https://www.newsdirect.com/newsroom/bluesight-tracks-340b-dollars-from-invoice-to-rebate-as-2027-brings-new-financial-and-operational-challenges/ Thu, 19 Nov 2026 13:00:10 +0000 https://www.newsdirect.com/?p=55113 Alexandria, Virginia, November 19th, 2026, NewsDirect

Hospitals have saved nearly $200 million with Bluesight’s cost-saving tools. In 2027, new capabilities further grow margins and capture 340B dollars. 

Bluesight, the leader in hospital intelligence solutions, today announced new capabilities to support health systems as they face the 340B rebate pilot and other financial pressures. Bluesight will track 340B dollars from the wholesaler invoice through the claim, payment, and manufacturer’s rebate, while also enabling pharmacy teams to identify revenue opportunities within their purchasing workflows. 

In 2027, 340B transactions will pay less, cost more up front, and must be proven during a HRSA audit. The pay cut comes from CMS’s Outpatient Prospective Payment System (OPPS), which will reduce outpatient reimbursement for 340B-acquired drugs by 32%, an estimated $4.35 billion reduction in original Medicare drug payments in the first year. The up-front costs stem from HRSA’s 340B Rebate Model Pilot, which starts for 21 products from 10 manufacturers and requires organizations to pay wholesale acquisition cost up front, submit claims data, and wait for a rebate. 

Beyond OPPS payment cuts and the rebate pilot, hospitals face additional challenges that may impact their bottom line. Manufacturers are withholding 340B pricing from those that do not submit claims data, CMS is mandating reporting of every Medicare Part D 340B claim starting in 2027, and ongoing legislation in both chambers could further tighten 340B reporting and oversight. 

Bluesight will address hospitals’ financial concerns and provide new workflows that solve for changes in the 340B program: 

  • Submission: Each rebate-eligible claim will be identified and submitted to Beacon, the 340B rebate submission platform. 
  • Financial Reconciliation: A purchase-to-rebate ledger will match every rebate’s Beacon submission ID to the original wholesaler invoice, flagging fully paid, late, short, and denied rebates. Pharmacy and finance teams can then forecast cash flow and resolve late or denied rebates. 
  • Rebate Defense: The same audit record that proves each claim was eligible supports the hospital when a manufacturer or HRSA questions a claim or denies a rebate. 
  • Revenue Recovery: A TPA-independent, 100% claims audit will find missed opportunities to capture more revenue and savings, including eligible administrations and prescriptions that were never billed. 

These workflows build on the invoice data Bluesight already analyzes from more than 3,900 hospitals across more than 13,000 purchasing accounts – data that now allows each rebate to be matched to its original invoice.  

“Other vendors are building tools to automate rebate submissions,” said Kevin MacDonald, CEO and co-founder of Bluesight. “We’ve built that operational layer too, but with payment cuts, higher up-front costs, and a rebate wait all impacting finances, hospitals also need to know what each purchase earns, what is still owed, and where margin is being lost. We believe the financial impact will weigh heavier than the paperwork, and that is why we are focusing on more than just the submission workflow itself.” 

To further support financial transparency and growth across the pharmacy enterprise, Bluesight will release a Claims-Based Revenue Optimizer at the end of 2026 – expanding on the Medicare Revenue Optimizer feature launched earlier this year. This added view enables pharmacy and revenue teams to see the historical remittance rate for each drug based on their own payer mix, so before a drug is purchased, pharmacy teams can compare cost, reimbursement, and net margin. Early indicators from health systems piloting the capability show more than $20 million in annual revenue potential. Bluesight is also adding capture of missed 340B opportunities and revenue cycle insights, including denial trending and root cause analysis of underpayments. 

Bluesight’s 340B rebate solutions and revenue optimization capabilities are built for what pharmacy finances demand in 2027. Learn more at bluesight.com. 

About Bluesight

Bluesight powers hospital operations with intelligence that simplifies inventory management, procurement, and compliance. Through its suite of industry-leading solutions, Bluesight ensures that health systems protect every patient and optimize every dollar. Over 3,000 United States and Canadian hospitals rely on Bluesight every day to have efficient and safe operations. For more information, please visit bluesight.com.

Contact

Era Atre
[email protected]

]]>